Highly motivated Ph.D. research scientist with 9+ years of pre-clinical and translation research in the field of Hematology/Oncology, especially Acute Myeloid Leukemia (AML).
Expert in normal/ malignant stem cells, signal transduction, biomarkers and drug discovery/drug development using small molecules or cancer immunotherapy both in vitro and in vivo. Strong ability to plan, develop, and execute pre-clinical studies for oncology drugs with excellent communication skills, presentation abilities and work ethic.
Success driven team player able to work under pressure in order meet deadlines. Established collaborations with both academic and pharmaceutical companies.
With an ambitious personality, my goal is to develop selective therapeutic strategies for targeting AML/cancer stem cells in order to start clinical trials and improve patients’ outcome. As a proof, one of my preclinical study led to a phase I/II clinical trial combining dasatinib with conventional chemotherapy aimed at improving outcomes in poor-risk AML patients that otherwise have low remission rates and high relapse rates (NCT01876953).
Specialties: Hematological malignancies, especially AML, CML and MDS.
Normal hematopoietic and leukemic stem cells isolation/characterization, signaling pathways, AML/MDS patient-derived xenograft model and syngeneic/GEMM AML mouse model.
Pre-clinical, clinical and translational research.